BiOptix Diagnostics, Inc.
Diagnostic Instruments: Label-free Biodetectors and Bionanoslides
Shareholders in Portfolio Company
Investment Started: 2011
0.54 bln rubles
Co-investment by RUSNANO0.13 bln rubles
Production of label-free biodetectors and, in Russia, production of disposable bionanoslides, both developed by American company BiOptix Diagnostics, Inc.
BiOptix Diagnostics, Inc., in collaboration with 2005 Nobel Prize laureate in physics John Hall, has developed a unique technology for biodetection. The biodetectors developed by BiOptix provide extremely sensitive label-free biomolecule interaction analysis in real time. This kind of measurements is essential for development of promising molecular candidates for innovation drugs.
The BiOptix biodetector does not require florescent or isotope labeling of biomolecules. This saves time and reagents and, more importantly, facilitates study that was previously unachievable.
Areas of application
- Molecular diagnostics
- Pharmaceutical companies
- Scientific research institutes and universities
- Low acquisition and use costs
- Simplicity of use
05 March 2013
04 December 2012BiOptix Announces a New SPR Technology for Antibody Manufacturers and Researchers
News of Portfolio Company
08 November 2012BiOptix Announces the Launch of the BiOptix Innovators Program
Journal of Engineering
24 March 2011